Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9546496 | 0.85 | DDB1 (0.32) | CRBNDDB1TSHRGAA | |
| SCHEMBL9546586 | 0.85 | DDB1 (0.32) | CRBNDDB1TSHRGAA | |
| SCHEMBL9546756 | 0.85 | DDB1 (0.32) | CRBNDDB1TSHRGAA | |
| SCHEMBL9546746 | 0.85 | DDB1 (0.32) | CRBNDDB1TSHRGAA | |
| SCHEMBL20292600 | 0.83 | MAP3K14 (0.36) | CRBNDDB1MAP3K14GLATDP1 | |
| SCHEMBL4396268 | 0.82 | CRBN (0.35) | CRBNDDB1MAP3K14MEN1KMT2A | |
| SCHEMBL1773976 | 0.82 | CRBN (0.40) | CRBNDDB1GAAMAP3K14MEN1 | |
| SCHEMBL57232 | 0.81 | MAP3K14 (0.39) | CRBNDDB1TSHRGAAMAP3K14 | |
| SCHEMBL16049982 | 0.81 | ALDH1A1 (0.39) | GAACYP1A2HTTMEN1KMT2A | |
| SCHEMBL9546485 | 0.81 | MMP1 (0.36) | CRBNDDB1MAP3K14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2165709-B1 | Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent | AMBRILIA BIOPHARMA INC (CA) | 2016-03-16 | — | — | EP | disclosed |
| EP-1877091-B1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | TAIMED BIOLOG INC (TW) | 2015-03-25 | — | — | EP | disclosed |
| US-8742158-B2 | Protease inhibitors | TaiMed Biologies, Inc. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8580995-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | TAIMED BIOLOGICS, INC. (TW) | 2013-11-12 | — | — | US | disclosed |
| EP-1575914-B1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | TAIMED BIOLOG INC (TW) | 2013-10-16 | — | — | EP | disclosed |
| US-20130158261-A1 | PROTEASE INHIBITORS | TAIMED BIOLOGICS, INC. (TW) | 2013-06-20 | — | — | US | disclosed |
| US-8410300-B2 | Protease inhibitors | TAIMED BIOLOGICS, INC. (TW) | 2013-04-02 | — | — | US | disclosed |
| EP-2258681-B1 | Aromatic Derivatives as HIV Aspartyl Protease Inhibitors | TAIMED BIOLOG INC (TW) | 2012-09-26 | — | — | EP | disclosed |
| EP-2258680-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | TAIMED BIOLOG INC (TW) | 2012-09-19 | — | — | EP | disclosed |
| US-8227450-B2 | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation | AMBRILIA BIOPHARMA INC. (CA) | 2012-07-24 | — | — | US | disclosed |
| WO-2007062526-A1 | LYSINE-BASED PRODRUGS OF ASPARTYL PROTEASE INHIBITORS AND PROCESSES FOR THEIR PREPARATION | AMBRILIA BIOPHARMA INC. (CA) | 2007-06-07 | — | — | WO | disclosed |
| EP-1773763-A1 | LYSINE BASED COMPOUNDS | Ambrilia Biopharma Inc. (CA) | 2007-04-18 | — | — | EP | disclosed |
| US-20060287316-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-12-21 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006114001-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | AMBRILIA BIOPHARMA INC. (CA) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006012725-A1 | LYSINE BASED COMPOUNDS | AMBRILIA BIOPHARMA INC. (CA) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025592-A1 | Lysine based compounds | TAIMED BIOLOGICS, INC. (TW) | 2006-02-02 | — | — | US | disclosed |
| EP-1575914-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | Procyon Biopharma Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004056764-A1 | AROMATIC DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2004-07-08 | — | — | WO | disclosed |
| US-6632816-B1 | Aromatic derivatives as HIV aspartyl protease inhibitors | PHARMACOR INC. (CA) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025592-A1 | Lysine based compounds | DOT1L, H1-2, H1-0 | CRBN 1380/4885DDB1 4649/4885TSHR 1638/4885 |
| US-20060287316-A1 | METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS | SPINT2, PREP, F2RL1 | CRBN 1197/4885DDB1 3490/4885TSHR 3131/4885 |
| US-20130158261-A1 | PROTEASE INHIBITORS | PREP, CTRL, CTRB1 | CRBN 664/4885DDB1 3713/4885TSHR 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.